Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma, Stage IV Melanoma

About this trial
This is an interventional treatment trial for Recurrent Melanoma
Eligibility Criteria
Criteria: Histologically confirmed malignant melanoma of cutaneous origin Patients with unknown primary allowed Stage IV disease Measurable disease by physical examination, CT scan, MRI or plain x-ray Unresectable disease Residual or recurrent disease after prior surgery for stage IV disease allowed Residual tumor at the site of incomplete resection may be included only as nonmeasurable disease Must have serum lactate dehydrogenase (LDH) levels measured Must have tissue specimens available Negative brain CT scan or MRI within the past 42 days Creatinine =< 1.5 times ULN Absolute neutrophil count >= 1,000/mm^3 Platelet count >= 100,000/mm^3 Hemoglobin >= 9.0 g/dL Fasting cholesterol =< 350 mg/dL (lipid-lowering agents allowed) Triglycerides =< 300 mg/dL (lipid-lowering agents allowed) No symptomatic sensory neuropathy >= grade 2 No evidence of bleeding diathesis or coagulopathy No congestive heart failure No myocardial infarction within the past 2 months No New York Heart Association class III or IV heart disease No condition that impairs the ability to swallow pills (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, prior surgical procedure affecting absorption, or active peptic ulcer disease) No known allergy to imidazoles (e.g. clotrimazole, ketoconazole, miconazole, or econazole) No history of allergic reaction to compounds of similar chemical or biologic composition as tipifarnib No hypertension with systolic blood pressure (BP) > 140 mm Hg or diastolic BP > 90 mm Hg Patients with well-controlled hypertension allowed Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled diabetes No uncontrolled diabetes No active uncontrolled infection No other severe or uncontrolled medical disease No psychologic or medical condition that would preclude study treatment or compliance No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated stage I or II cancer that is in complete remission, or carcinoma in situ of the cervix At least 90 days since prior adjuvant therapy, including cytotoxic agents At least 28 days since prior radiotherapy At least 28 days since prior surgery to remove the tumor No prior systemic therapy for stage IV melanoma No prior therapy with agents targeting farnesyl transferase, the MAP kinase pathway, or vascular endothelial growth factors (VEGF) or receptors (VEFGR), including drugs such as sorafenib, temsirolimus, or tipifarnib Concurrent lipid-lowering agents allowed Not requiring full-dose anticoagulation for recent thrombotic event No concurrent highly active antiretroviral therapy (HAART) in HIV-positive patients No concurrent use of any of the following: dilantin; carbamazepine; Phenobarbital; rifampin; hypericum perforatum (St. John's wort); ketoconazole; itraconazole; ritonavir; cyclosporine; phenytoin; grapefruit juice Bilirubin =< 1.5 times upper limit of normal (ULN) SGOT or SGPT =< 2.5 times ULN (5 times ULN if hepatic metastases) No history of brain metastases Zubrod performance status 0-1
Sites / Locations
- University of Arkansas for Medical Sciences
- East Bay Radiation Oncology Center
- Eden Hospital Medical Center
- Valley Medical Oncology Consultants-Castro Valley
- Valley Medical Oncology Consultants-Fremont
- University of Southern California/Norris Cancer Center
- Contra Costa Regional Medical Center
- El Camino Hospital
- Highland General Hospital
- Alta Bates Summit Medical Center - Summit Campus
- Bay Area Breast Surgeons Inc
- Bay Area Tumor Institute CCOP
- Larry G Strieff MD Medical Corporation
- Tom K Lee Inc
- Valley Care Health System - Pleasanton
- Valley Medical Oncology Consultants
- Sutter Roseville Medical Center
- Sutter General Hospital
- Doctors Medical Center- JC Robinson Regional Cancer Center
- The Medical Center of Aurora
- Boulder Community Hospital
- Penrose-Saint Francis Healthcare
- Porter Adventist Hospital
- Exempla Saint Joseph Hospital
- Presbyterian - Saint Lukes Medical Center - Health One
- Rose Medical Center
- Colorado Cancer Research Program CCOP
- Swedish Medical Center
- Saint Mary's Hospital and Regional Medical Center
- North Colorado Medical Center
- Saint Anthony Hospital
- Sky Ridge Medical Center
- Longmont United Hospital
- McKee Medical Center
- Saint Mary Corwin Medical Center
- North Suburban Medical Center
- Exempla Lutheran Medical Center
- Cancer Centers of Central Florida PA
- Northeast Georgia Medical Center
- Memorial Health University Medical Center
- South Georgia Medical Center
- Rush - Copley Medical Center
- Decatur Memorial Hospital
- Joliet Oncology-Hematology Associates Limited
- Loyola University Medical Center
- Garneau, Stewart C MD (UIA Investigator)
- Porubcin, Michael MD (UIA Investigator)
- Sharis, Christine M MD (UIA Investigator)
- Stoffel, Thomas J MD (UIA Investigator)
- Memorial Medical Center
- Carle Cancer Center
- Carle Clinic-Urbana Main
- Franciscan Saint Anthony Health-Michigan City
- McFarland Clinic PC-William R Bliss Cancer Center
- Constantinou, Costas L MD (UIA Investigator)
- Medical Oncology and Hematology Associates-West Des Moines
- Genesis Medical Center - East Campus
- Genesis Medical Center - West Campus
- Mercy Capitol
- Iowa Methodist Medical Center
- Iowa Oncology Research Association CCOP
- Medical Oncology and Hematology Associates-Des Moines
- Medical Oncology and Hematology Associates-Laurel
- Mercy Medical Center - Des Moines
- Iowa Lutheran Hospital
- Siouxland Hematology Oncology Associates
- Mercy Medical Center-Sioux City
- Saint Luke's Regional Medical Center
- Hospital District Sixth of Harper County
- Cancer Center of Kansas - Chanute
- Cancer Center of Kansas - Dodge City
- Cancer Center of Kansas - El Dorado
- Cancer Center of Kansas - Fort Scott
- Hays Medical Center
- Promise Regional Medical Center-Hutchinson
- Cancer Center of Kansas-Independence
- Providence Medical Center
- University of Kansas Medical Center
- Cancer Center of Kansas-Kingman
- Lawrence Memorial Hospital
- Cancer Center of Kansas - Newton
- Olathe Cancer Center
- Radiation Oncology Practice Corporation Southwest
- Cancer Center of Kansas - Parsons
- Cancer Center of Kansas - Pratt
- Cancer Center of Kansas - Salina
- Stormont-Vail Regional Health Center
- Saint Francis Hospital and Medical Center - Topeka
- Cancer Center of Kansas - Wellington
- Associates In Womens Health
- Cancer Center of Kansas-Wichita Medical Arts Tower
- Cancer Center of Kansas - Main Office
- Via Christi Regional Medical Center
- Wichita CCOP
- Cancer Center of Kansas - Winfield
- Louisiana State University Sciences Center- Monroe
- Highland Clinic
- Louisiana State University Health Sciences Center Shreveport
- Boston Medical Center
- University of Michigan
- Bronson Battle Creek
- Spectrum Health Big Rapids Hospital
- Wayne State University/Karmanos Cancer Institute
- Henry Ford Hospital
- Grand Rapids Clinical Oncology Program
- Mercy Health Saint Mary's
- Spectrum Health at Butterworth Campus
- Holland Community Hospital
- Mercy Health Partners-Hackley Campus
- Mercy Health Mercy Campus
- Munson Medical Center
- Metro Health Hospital
- Meeker County Memorial Hospital
- Virginia Piper Cancer Institute
- Southeast Missouri Hospital
- Centerpoint Medical Center LLC
- Radiation Oncology Practice Corporation South
- Radiation Oncology Practice Corporation - North
- Montana Cancer Consortium CCOP
- Northern Rockies Radiation Oncology Center
- Saint Vincent Healthcare
- Hematology-Oncology Centers of the Northern Rockies PC
- Billings Clinic
- Bozeman Deaconess Cancer Center
- Bozeman Deaconess Hospital
- Saint James Community Hospital and Cancer Treatment Center
- Berdeaux, Donald MD (UIA Investigator)
- Great Falls Clinic
- Northern Montana Hospital
- Saint Peter's Community Hospital
- Glacier Oncology PLLC
- Kalispell Medical Oncology
- Kalispell Regional Medical Center
- Community Medical Hospital
- Montana Cancer Specialists
- Saint Patrick Hospital - Community Hospital
- Guardian Oncology and Center for Wellness
- Good Samaritan Hospital
- Nebraska Cancer Research Center
- University Medical Center of Southern Nevada
- Nevada Cancer Research Foundation CCOP
- Mary Imogene Bassett Hospital
- Orange Regional Medical Center
- Mission Hospital-Memorial Campus
- Rutherford Hospital
- University of Cincinnati
- Mansfield General Hospital-MedCentral Health System
- Adventist Medical Center
- SWOG
- Delaware County Memorial Hospital
- Thomas Jefferson University Hospital
- AnMed Health Hospital
- Spartanburg Regional Medical Center
- Upstate Carolina CCOP
- Huntsman Cancer Institute/University of Utah
- Danville Regional Medical Center
- Southwest VA Regional Cancer Center
- PeaceHealth Saint Joseph Medical Center
- Harrison HealthPartners Hematology and Oncology-Bremerton
- Columbia Basin Hematology and Oncology PLLC
- Skagit Valley Hospital
- Harborview Medical Center
- Minor and James Medical PLLC
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Group Health Cooperative-Seattle
- Swedish Medical Center-First Hill
- The Polyclinic
- University of Washington Medical Center
- United General Hospital
- Cancer Care Northwest - Spokane South
- Wenatchee Valley Medical Center
- Dean Hematology and Oncology Clinic
- Welch Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm I (sorafenib, temsirolimus)
Arm II (sorafenib, tipifarnib)
Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21